Sibylle Loibl

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had rec...

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after comp...

Breast cancer